Lupin ties up with Japan-based Nichi-Iko for biosimilar launch

Lupin ties up with Japan-based Nichi-Iko for biosimilar launch

2018-06-18T11:21:47+00:00 On

Indian Pharma major Lupin said it has signed an agreement with Japan-based generics maker Nichi-Iko to market its upcoming biosimilar drug, Etanercept, in the far eastern nation. Etanercept, already approved in the US, is used to treat inflammatory conditions. It is pending…

Alembic Pharma gets nod for doxycylcine antibiotic in the US

Alembic Pharma gets nod for doxycylcine antibiotic in the US

2018-06-14T11:04:29+00:00 On

Alembic Pharmaceuticals said the USFDA has permitted it to sell antibiotic doxycycline in the US market. Doxycycline Hyclate Capsules USP, 50 mg and 100 mg, are considered a medium sized drug from a market perspective and had sales of US$ 80 million…

Fortis Healthcare drops plan to demerge SRL Diagnostics

Fortis Healthcare drops plan to demerge SRL Diagnostics

2018-06-14T09:17:20+00:00 On

Fortis Healthcare said it has cancelled its plan to demerge and list its diagnostics arm, SRL Ltd, and will withdraw the concerned application before the authorities. “The Scheme is currently pending for approval with the National Company Law Tribunal, Chandigarh Bench. Further,…

Cipla to sell Eli Lilly’s Basaglar insulin in India

Cipla to sell Eli Lilly’s Basaglar insulin in India

2018-06-08T13:03:14+00:00 On

Indian pharmaceutical giant Cipla Ltd said it would sell Eli Lilly and Co’s insulin glargine in India. Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. Unlike regular insulin shots —…

USFDA completes inspection at Zydus’ Ahmedabad plant

USFDA completes inspection at Zydus’ Ahmedabad plant

2018-06-06T09:53:42+00:00 On

Pharmaceuticals maker Zydus Cadila said the USFDA has completed an inspection of its injectables manufacturing plant at Ahmedabad with zero observations. No observations is good news for pharma manufacturers as it indicates that the inspectors found everything to order. The inspection of…

Fortis Healthcare calls for fresh bids from all three parties

Fortis Healthcare calls for fresh bids from all three parties

2018-05-29T15:44:57+00:00 On

Fortis Healthcare Ltd said it has decided to call for fresh bids for investing into the company for a controlling stake. The move follows a messy proposals and counter-proposals by the three main bidders — a team of promoters of Hero MotoCorp…

Strides Shasun denies rumors of auditor resignation

Strides Shasun denies rumors of auditor resignation

2018-05-29T09:51:21+00:00 On

Pharma major Strides Shasun denied rumors that its auditors had resigned. The rumors, coming close on the heels of a similar development at Manpasand Beverages, had impacted the company’s share price today morning. Shares of Strides Shasun fell to a low of…

Sun Pharma launches authorized version of Daiichi Sankyo’s cholesterol drug in the US

Sun Pharma launches authorized version of Daiichi Sankyo’s cholesterol drug in the US

2018-05-18T08:00:10+00:00 On

India-based Sun Pharmaceutical Industries said it has launched an authorized generic version for Daiichi Sankyo’s cholesterol drug Welchol in the US market. The drug, whose compound name is colesevelam hydrochloride, had US sales of approximately US$ 520 million for the 12 months…

Suven Life Sciences wins 2 patents in Australia,  1 in Singapore

Suven Life Sciences wins 2 patents in Australia, 1 in Singapore

2018-05-17T10:55:26+00:00 On

Pharma player Suven Life Sciences said it received two patents from Australia and one from Singapore for new drugs that can be used for the treatment of disorders associated with Neurodegenerative diseases. “The granted patents include the class of selective H3 Inverse…

Strides Shasun, Apotex to merge Australian ops to create biggest generics player

Strides Shasun, Apotex to merge Australian ops to create biggest generics player

2018-05-09T12:07:22+00:00 On

Pharma player Strides Shasun said it has agreed in principle to merge its Australian business with the Australian operations of peer Apotex. Both have substantial businesses in Australia; Strides under the Arrow brand and Apotex under its primary brand. The merger will…

Malaysia’s IHH Healthcare releases details of Rs 4,000 cr bid for Fortis Healthcare

Malaysia’s IHH Healthcare releases details of Rs 4,000 cr bid for Fortis Healthcare

2018-04-24T17:27:08+00:00 On

Malaysia’s IHH Healthcare has come out with a binding offer to invest Rs 650 cr in Fortis Healthcare, and follow it up with Rs 3,350 cr after conducting three weeks of due diligence on the company’s account books. The move competes with…

USFDA approves Dr Reddy Lab’s UK plant after seven-month scrutiny

USFDA approves Dr Reddy Lab’s UK plant after seven-month scrutiny

2018-04-24T12:17:22+00:00 On

The United States Food & Drugs Administration has closed its audit of the UK manufacturing plant of Dr Reddy’s Laboratories, the Indian pharmaceutical company said. In September last year, the company had announced that the US FDA issued a Form 483 with…

Lupin gets USFDA nod for generic version of Valeant’s Xenazine

Lupin gets USFDA nod for generic version of Valeant’s Xenazine

2018-04-23T12:40:08+00:00 On

Pharma major Lupin said it received final approval for to launch a generic version of Valeant Pharmaceuticals’ Xenazine in the US. Tetrabenazine Tablets, 12.5 mg and 25 mg, has annual sales of approximately USD 288.1 million in the US, according to IQVIA….

Fortis Healthcare sets up expert committee to evaluate all bids

Fortis Healthcare sets up expert committee to evaluate all bids

2018-04-19T17:14:55+00:00 On

Hospital chain Fortis Healthcare said it has set up a special committee to evaluate the bids submitted by various parties to invest money into the company. It said the company has received binding offers from the Manipal – TPG consortium and the…

Zydus Cadila gets USFDA nod for NSAID Diclofenac Sodium

Zydus Cadila gets USFDA nod for NSAID Diclofenac Sodium

2018-04-19T09:55:39+00:00 On

Pharmaceuticals maker Zydus Cadila said it received the final approval from the USFDA to market inflammation solution Diclofenac Sodium in the country. Diclofenac Sodium topical solution, 1.5%, is a non-steroidal anti-inflammatory drug (NSAID) used for symptomatic treatment of osteoarthritis of the knee….

Munjals and Burmans sweeten their offer for Fortis Healthcare, drop conditions

Munjals and Burmans sweeten their offer for Fortis Healthcare, drop conditions

2018-04-19T09:08:58+00:00 On

Embattled hospital chain Fortis Healthcare said it received an improved combined offer from the Munjals of Hero MotoCorp and the Burmans of Dabur Ltd. Under the revised terms, the investors are willing to invest Rs 1,500 cr, against the Rs 1,250 cr…